Physician profile
Kevin T Murphy
NPI 1730104167
$10,198.30
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $17.60 · 2022: $310 · 2023: $265 · 2024: $8,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,843 · Travel and Lodging: $692 · Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,843.00 |
| Travel and Lodging | $692.00 |
| Food and Beverage | $400.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,715.22 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $383.07 | 2019-2023 | Imbruvica, Epkinly |
| Viewray Technologies INC | $208.43 | 2022 | |
| Merck Sharp & Dohme LLC | $115.21 | 2019 | |
| Amgen INC. | $109.62 | 2019 | |
| Tersera Therapeutics LLC | $103.36 | 2019 | |
| Celgene Corporation | $90.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.22 | 2019 | |
| Seagen INC. | $71.39 | 2019-2020 | |
| Incyte Corporation | $68.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.95 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $27.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.97 | 2019 | |
| Eisai INC. | $20.54 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $18.82 | 2019 | |
| Abbvie INC. | $18.18 | 2019 | |
| Puma Biotechnology, INC. | $17.76 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $17.75 | 2019 | |
| Astellas Pharma US INC | $16.77 | 2019 | |
| Daiichi Sankyo INC. | $16.31 | 2019 | |
| Advanced Accelerator Applications | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.